Opinion statement Dual antiplatelet therapy with a combination of aspirin and an inhibitor of
the ADP P2Y 12 receptor is the recommended treatment for patients with acute coronary …

Dual antiplatelet therapy, with aspirin plus a P2Y12 inhibitor agent, remains the cornerstone
treatment after percutaneous coronary intervention. However, significant proportion of …

Platelets are key mediators in the pathophysiology of atherothrombotic disease.
Inappropriate platelet activation can lead to thrombosis and ischemic events. Platelet …

Dual antiplatelet therapy, consisting of aspirin and a P2Y12 receptor inhibitor, has
dramatically reduced the incidence of atherothrombotic events for patients with acute …

Dual oral antiplatelet therapy with aspirin and clopidogrel is the therapy of choice in patients
with acute coronary syndromes and in patients undergoing coronary stent placement to …

Oral antiplatelet therapy is routinely administered to ACS patients as well as to patients
undergoing percutaneous coronary intervention (PCI) with the primary aim of inhibiting …

Guidelines provide a Class IA recommendation for the use of dual antiplatelet therapy in
patients undergoing percutaneous coronary intervention (PCI). However, there is …

Platelet function testing has evolved from crude tests, such as the bleeding time, to tests that
permit a relatively sophisticated evaluation of platelet activity. Nonetheless, these tests are …

The ability to test platelet reactivity in clinical practice could help in making informed
decisions on both initiation and titration of anti-platelet drug therapies. However, many …

Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist is the cornerstone of
management in patients with acute coronary syndrome and those with coronary artery …